1. Cell Cycle/DNA Damage Cytoskeleton Anti-infection Apoptosis
  2. Microtubule/Tubulin Fungal Apoptosis Antibiotic Bacterial
  3. Epothilone B

Epothilone B  (Synonyms: EPO 906; Patupilone)

Cat. No.: HY-17029 Purity: 99.91%
SDS COA Handling Instructions Technical Support

Epothilone B is a microtubule stabilizer with a Ki of 0.71μM. It acts by binding to the αβ-tubulin heterodimer subunit which causes decreasing of αβ-tubulin dissociation.

For research use only. We do not sell to patients.

Epothilone B Chemical Structure

Epothilone B Chemical Structure

CAS No. : 152044-54-7

Size Price Stock Quantity
Free Sample (0.1 - 0.5 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
2 mg In-stock
5 mg In-stock
10 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 5 publication(s) in Google Scholar

Top Publications Citing Use of Products
  • Biological Activity

  • Protocol

  • Purity & Documentation

  • References

  • Customer Review

Description

Epothilone B is a microtubule stabilizer with a Ki of 0.71μM. It acts by binding to the αβ-tubulin heterodimer subunit which causes decreasing of αβ-tubulin dissociation.

IC50 & Target

EC0.01: 1.8 μM (Microtubule/Tubulin)[1]

Cellular Effect
Cell Line Type Value Description References
A2780 EC50
4 nM
Compound: Epothilone B
Antiproliferative activity against D4-9-31 resistance human A2780 cells incubated for 72 hrs by ATPlite reagent based assay
Antiproliferative activity against D4-9-31 resistance human A2780 cells incubated for 72 hrs by ATPlite reagent based assay
[PMID: 31047749]
A2780 EC50
5.2 nM
Compound: Epothilone B
Antiproliferative activity against human A2780 cells incubated for 72 hrs by ATPlite reagent based assay
Antiproliferative activity against human A2780 cells incubated for 72 hrs by ATPlite reagent based assay
[PMID: 31047749]
A-431 IC50
67 μM
Compound: Epothilone B
Cytotoxicity against human A-431 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay
Cytotoxicity against human A-431 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay
[PMID: 35175766]
A-431 IC50
7.3 x 10-5 μM
Compound: Epothilone B
Cytotoxicity against human A431 cells assessed as reduction in cell viability after 5 days by MTT assay
Cytotoxicity against human A431 cells assessed as reduction in cell viability after 5 days by MTT assay
[PMID: 28398049]
A-431 IC50
7.9 x 10-5 μM
Compound: Epothilone B
Cytotoxicity against human A431 cells assessed as reduction in cell growth incubated for 5 days by MTT assay
Cytotoxicity against human A431 cells assessed as reduction in cell growth incubated for 5 days by MTT assay
[PMID: 31599583]
A549 GI50
0.7 nM
Compound: Epothilone B
Growth inhibition of human A549 cells after 4 days by SRB assay
Growth inhibition of human A549 cells after 4 days by SRB assay
[PMID: 28740601]
A549 IC50
1.5 x 10-4 μM
Compound: Epothilone B
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 5 days by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 5 days by MTT assay
[PMID: 28398049]
A549 IC50
4 nM
Compound: Epothilone B
Cytotoxicity against human A549 cells measured after 5 days by MTT assay
Cytotoxicity against human A549 cells measured after 5 days by MTT assay
[PMID: 31021629]
A549 IC50
6.9 x 10-5 μM
Compound: Epothilone B
Cytotoxicity against human A549 cells assessed as reduction in cell growth incubated for 5 days by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell growth incubated for 5 days by MTT assay
[PMID: 31599583]
A549 IC50
88 μM
Compound: Epothilone B
Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay
Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay
[PMID: 35175766]
Bel-7402 IC50
0.9 nM
Compound: Epothilone B
Antiproliferative activity against human Bel7402 after 72 hrs by CellTiter Glo assay
Antiproliferative activity against human Bel7402 after 72 hrs by CellTiter Glo assay
[PMID: 22320354]
HCC1937 IC50
> 10 μM
Compound: Epothilone B
Antiproliferative activity against exponentially growing adherent human HCC1937 cells assessed as inhibition of cell proliferation after 72 hrs by luminescence detection based ATPlite assay
Antiproliferative activity against exponentially growing adherent human HCC1937 cells assessed as inhibition of cell proliferation after 72 hrs by luminescence detection based ATPlite assay
[PMID: 25872984]
Hep 3B2 IC50
> 100 nM
Compound: Epothilone B
Antiproliferative activity against human Hep3B after 72 hrs by CellTiter Glo assay
Antiproliferative activity against human Hep3B after 72 hrs by CellTiter Glo assay
[PMID: 22320354]
HepG2 EC50
0.01 μM
Compound: Epothilone B
Activation of rat PXR expressed in human HepG2 cells after 24 hrs by luciferase reporter gene based luminescent analysis
Activation of rat PXR expressed in human HepG2 cells after 24 hrs by luciferase reporter gene based luminescent analysis
[PMID: 20966043]
HepG2 EC50
12.6 μM
Compound: Epothilone B
Activation of human PXR expressed in human HepG2 (DPX-2) cells after 24 hrs by luciferase reporter gene based luminescent analysis
Activation of human PXR expressed in human HepG2 (DPX-2) cells after 24 hrs by luciferase reporter gene based luminescent analysis
[PMID: 20966043]
HepG2 IC50
44.7 nM
Compound: Epothilone B
Antiproliferative activity against human HepG2 after 72 hrs by CellTiter Glo assay
Antiproliferative activity against human HepG2 after 72 hrs by CellTiter Glo assay
[PMID: 22320354]
Huh-7 IC50
4.5 nM
Compound: Epothilone B
Antiproliferative activity against human HuH7 after 72 hrs by CellTiter Glo assay
Antiproliferative activity against human HuH7 after 72 hrs by CellTiter Glo assay
[PMID: 22320354]
HUVEC IC50
0.00055 μM
Compound: Epothilone B
Cytotoxicity against HUVEC after 5 days by MTT assay
Cytotoxicity against HUVEC after 5 days by MTT assay
[PMID: 27231731]
KB IC50
0.18 nM
Compound: Epothilone B
Concentration required to inhibit the growth of paclitaxel-resistant human epidermoid carcinoma cells KB-8511 by 50 percent (72 hr exposure)
Concentration required to inhibit the growth of paclitaxel-resistant human epidermoid carcinoma cells KB-8511 by 50 percent (72 hr exposure)
[PMID: 11133086]
KB 3-1 IC50
0.00022 μM
Compound: Epothilone B
Cytotoxicity against human KB 3.1 cells after 5 days by MTT assay
Cytotoxicity against human KB 3.1 cells after 5 days by MTT assay
[PMID: 27231731]
KB 3-1 IC50
0.19 nM
Compound: Epothilone B
Concentration required to inhibit the growth of paclitaxel-sensitive human epidermoid carcinoma cells KB-31 by 50 percent (72 hr exposure)
Concentration required to inhibit the growth of paclitaxel-sensitive human epidermoid carcinoma cells KB-31 by 50 percent (72 hr exposure)
[PMID: 11133086]
KB 3-1 IC50
0.22 μM
Compound: Epothilon B
Cytotoxicity against human KB 3.1 cells assessed as inhibition of cell growth after 5 days by MTT assay
Cytotoxicity against human KB 3.1 cells assessed as inhibition of cell growth after 5 days by MTT assay
[PMID: 29489350]
KB 3-1 IC50
5.3 x 10-5 μM
Compound: Epothilone B
Cytotoxicity against human KB3-1 cells measured after 5 days by MTT assay
Cytotoxicity against human KB3-1 cells measured after 5 days by MTT assay
[PMID: 31021629]
KB 3-1 IC50
6.1 x 10-5 μM
Compound: Epothilone B
Cytotoxicity against human KB3-1 cells assessed as reduction in cell viability after 5 days by MTT assay
Cytotoxicity against human KB3-1 cells assessed as reduction in cell viability after 5 days by MTT assay
[PMID: 28398049]
KB 3-1 IC50
69 μM
Compound: Epothilone B
Cytotoxicity against human KB 3-1 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay
Cytotoxicity against human KB 3-1 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay
[PMID: 35175766]
KB 3-1 IC50
8.9 x 10-5 μM
Compound: Epothilone B
Cytotoxicity against human KB3-1 cells assessed as reduction in cell growth incubated for 5 days by MTT assay
Cytotoxicity against human KB3-1 cells assessed as reduction in cell growth incubated for 5 days by MTT assay
[PMID: 31599583]
KB 3-1 IC50
8.9 x 10-5 μM
Compound: Epothilon B
Cytotoxicity against human KB3.1 cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human KB3.1 cells assessed as reduction in cell viability by MTT assay
[PMID: 32786884]
L929 IC50
1.4 mM
Compound: Epothilone B
Cytotoxicity against mouse L929 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay
Cytotoxicity against mouse L929 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay
[PMID: 35175766]
L929 IC50
1.4 nM
Compound: Epothilone B
Cytotoxicity against mouse L929 cells assessed as reduction in cell growth incubated for 5 days by MTT assay
Cytotoxicity against mouse L929 cells assessed as reduction in cell growth incubated for 5 days by MTT assay
[PMID: 31599583]
L929 IC50
1.4 μM
Compound: Epothilon B
Cytotoxicity against mouse L929 cells assessed as inhibition of cell growth after 5 days by MTT assay
Cytotoxicity against mouse L929 cells assessed as inhibition of cell growth after 5 days by MTT assay
[PMID: 29489350]
L929 IC50
1.7 nM
Compound: Epothilone B
Cytotoxicity against mouse L929 cells assessed as reduction in cell viability after 5 days by MTT assay
Cytotoxicity against mouse L929 cells assessed as reduction in cell viability after 5 days by MTT assay
[PMID: 28398049]
L929 IC50
2.6 nM
Compound: Epothilon B
Cytotoxicity against mouse L929 cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against mouse L929 cells assessed as reduction in cell viability by MTT assay
[PMID: 32786884]
L929 IC50
7.5 x 10-4 μM
Compound: Epothilone B
Cytotoxicity against mouse L929 cells measured after 5 days by MTT assay
Cytotoxicity against mouse L929 cells measured after 5 days by MTT assay
[PMID: 31021629]
MCF7 ED50
0.0015 μM
Compound: 1b
Cytotoxicity against human MCF7 cells by phototoxicity labeling study
Cytotoxicity against human MCF7 cells by phototoxicity labeling study
[PMID: 19428248]
MCF7 IC50
1.5 x 10-4 μM
Compound: Epothilone B
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 5 days by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 5 days by MTT assay
[PMID: 28398049]
MCF7 IC50
2.4 x 10-4 μM
Compound: Epothilone B
Cytotoxicity against human MCF7 cells assessed as reduction in cell growth incubated for 5 days by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell growth incubated for 5 days by MTT assay
[PMID: 31599583]
MCF7 IC50
38.17 nM
Compound: Epothilone B
Antiproliferative activity against human MCF7 cells after 2 days by MTT assay
Antiproliferative activity against human MCF7 cells after 2 days by MTT assay
[PMID: 30318441]
MCF7 IC50
7.4 x 10-5 μM
Compound: Epothilone B
Cytotoxicity against human MCF7 cells measured after 5 days by MTT assay
Cytotoxicity against human MCF7 cells measured after 5 days by MTT assay
[PMID: 31021629]
MCF7 IC50
81 μM
Compound: Epothilone B
Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay
Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay
[PMID: 35175766]
MHCC97H IC50
6.7 nM
Compound: Epothilone B
Antiproliferative activity against human MHCC97H after 72 hrs by CellTiter Glo assay
Antiproliferative activity against human MHCC97H after 72 hrs by CellTiter Glo assay
[PMID: 22320354]
PC-3 IC50
1.6 nM
Compound: Epothilone B
Cytotoxicity against human PC3 cells assessed as reduction in cell growth incubated for 5 days by MTT assay
Cytotoxicity against human PC3 cells assessed as reduction in cell growth incubated for 5 days by MTT assay
[PMID: 31599583]
PC-3 GI50
1.7 nM
Compound: Epothilone B
Growth inhibition of human PC3 cells after 4 days by SRB assay
Growth inhibition of human PC3 cells after 4 days by SRB assay
[PMID: 28740601]
PC-3 IC50
2.2 nM
Compound: Epothilone B
Cytotoxicity against human PC3 cells measured after 5 days by MTT assay
Cytotoxicity against human PC3 cells measured after 5 days by MTT assay
[PMID: 31021629]
PC-3 IC50
2.5 x 10-4 μM
Compound: Epothilone B
Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 5 days by MTT assay
Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 5 days by MTT assay
[PMID: 28398049]
PC-3 IC50
71 μM
Compound: Epothilone B
Cytotoxicity against human PC-3 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay
Cytotoxicity against human PC-3 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay
[PMID: 35175766]
PLC-PRF-5 IC50
12.7 nM
Compound: Epothilone B
Antiproliferative activity against human PLC/PRF/5 after 72 hrs by CellTiter Glo assay
Antiproliferative activity against human PLC/PRF/5 after 72 hrs by CellTiter Glo assay
[PMID: 22320354]
SK-OV-3 IC50
0.29 mM
Compound: Epothilone B
Cytotoxicity against human SK-OV-3 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay
Cytotoxicity against human SK-OV-3 cells assessed as inhibition of cell proliferation incubated for 5 days by MTT assay
[PMID: 35175766]
SK-OV-3 IC50
2.36 x 10-5 μM
Compound: Epothilone B
Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability after 5 days by MTT assay
Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability after 5 days by MTT assay
[PMID: 28398049]
SK-OV-3 IC50
2.4 x 10-4 μM
Compound: Epothilone B
Cytotoxicity against human SKOV3 cells measured after 5 days by MTT assay
Cytotoxicity against human SKOV3 cells measured after 5 days by MTT assay
[PMID: 31021629]
SK-OV-3 IC50
2.8 x 10-4 μM
Compound: Epothilone B
Cytotoxicity against human SKOV3 cells assessed as reduction in cell growth incubated for 5 days by MTT assay
Cytotoxicity against human SKOV3 cells assessed as reduction in cell growth incubated for 5 days by MTT assay
[PMID: 31599583]
SMMC-7721 IC50
2.3 nM
Compound: Epothilone B
Antiproliferative activity against human SMMC7721 after 72 hrs by CellTiter Glo assay
Antiproliferative activity against human SMMC7721 after 72 hrs by CellTiter Glo assay
[PMID: 22320354]
SNU-182 IC50
22.3 nM
Compound: Epothilone B
Antiproliferative activity against human SNU182 after 72 hrs by CellTiter Glo assay
Antiproliferative activity against human SNU182 after 72 hrs by CellTiter Glo assay
[PMID: 22320354]
SNU-387 IC50
20 nM
Compound: Epothilone B
Antiproliferative activity against human SNU387 after 72 hrs by CellTiter Glo assay
Antiproliferative activity against human SNU387 after 72 hrs by CellTiter Glo assay
[PMID: 22320354]
SNU-398 IC50
2.9 nM
Compound: Epothilone B
Antiproliferative activity against human SNU398 after 72 hrs by CellTiter Glo assay
Antiproliferative activity against human SNU398 after 72 hrs by CellTiter Glo assay
[PMID: 22320354]
SNU-423 IC50
10.3 nM
Compound: Epothilone B
Antiproliferative activity against human SNU423 after 72 hrs by CellTiter Glo assay
Antiproliferative activity against human SNU423 after 72 hrs by CellTiter Glo assay
[PMID: 22320354]
SNU-449 IC50
19.9 nM
Compound: Epothilone B
Antiproliferative activity against human SNU449 after 72 hrs by CellTiter Glo assay
Antiproliferative activity against human SNU449 after 72 hrs by CellTiter Glo assay
[PMID: 22320354]
SNU-475 IC50
11.6 nM
Compound: Epothilone B
Antiproliferative activity against human SNU475 after 72 hrs by CellTiter Glo assay
Antiproliferative activity against human SNU475 after 72 hrs by CellTiter Glo assay
[PMID: 22320354]
U2OS IC50
1.04 x 10-4 μM
Compound: Epothilone B
Cytotoxicity against human U2OS cells assessed as reduction in cell viability after 5 days by MTT assay
Cytotoxicity against human U2OS cells assessed as reduction in cell viability after 5 days by MTT assay
[PMID: 28398049]
In Vitro

Epothilone B inhibits HCT116 cells with IC50 of 0.8 nM in HCT-116 cell line cytotoxicity assay[1]. Epothilone B (Patupilone) is a microtubule (MT) targeting agent. As shown by MTT cell proliferation assay, after 72 h of treatment Epothilone B efficiently inhibits cell growth with an IC50 of 6 nM, while concentrations ≤1 nM are not cytotoxic. Epothilone B significantly inhibits transwell cell migration at the non-cytotoxic concentration of 1 nM, and the effect is more evident at 10 nM[2]. Epothilone B (Patupilone) is a novel, non-taxane-related and nonneurotoxic microtubule-stabilizing agent in human medulloblastoma cell lines. Epothilone B reduces the proliferative activity in the D341 cell line, with an IC50 of 0.53 nM; in the D425Med cell line, with an IC50 of 0.37 nM; and in the DAOY cell line, with an IC50 of 0.19 nM. In the D341Med cell line, the effect of Epothilone B on clonogenic survival is at dose range of Epothilone B similar to the level of proliferative activity and viability (IC50, 0.50-0.75 nM). However, the clonogenicity of D425Med and DAOY cells is already strongly reduced at a 10-fold lower concentration of Epothilone B (IC50, 30 pM). These results overall demonstrate that Epothilone B is highly potent against different medulloblastoma cell lines[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Treatment with Epothilone B (Patupilone) or ionizing radiation alone results in a partial tumor growth suppression over 10 days, whereas combined treatment exerts a strong supra-additive tumor growth control, with complete tumor regression in the follow-up period (P<0.005, for ionizing radiation or Epothilone B alone vs combined treatment)[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial
Molecular Weight

507.68

Formula

C27H41NO6S

CAS No.
Appearance

Solid

Color

White to off-white

SMILES

O=C(C[C@H](O)C1(C)C)O[C@H](/C(C)=C/C2=CSC(C)=N2)C[C@]3([H])O[C@]3(C)CCC[C@H](C)[C@H](O)[C@@H](C)C1=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (196.97 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.9697 mL 9.8487 mL 19.6974 mL
5 mM 0.3939 mL 1.9697 mL 3.9395 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.08 mg/mL (4.10 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.08 mg/mL (4.10 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.91%

References
Kinase Assay
[3]

Asp-Glu-Val-Asp (DEVD)ase activity is determined in cytosolic cell extracts. Cells are treated with increasing concentrations of Epothilone B (Patupilone) for 6, 12, 24, and 48 h. Cells are harvested thereafter by trypsin/EDTA, centrifuged, and washed with precooled PBS. The cell pellet is suspended in 5 volumes of precooled buffer A (20 mM HEPES-KOH [pH 7.5], 10 mM KCl, 1.5 mM MgCl2, 1 mM sodium EDTA, 1 mM sodium EGTA, 1 mM dithiothreitol [DDT], 250 mM sucrose, and 0.1 mM phenylmethylsulfonyl fluoride [PMSF] supplemented with protease inhibitors [5 mg/mL pepstatin A, 10 mg/mL leupeptin, 2 mg/mL aprotinin, 2 mg/mL DTT, and 1 mM of PMSF]). After incubation on ice for 15 min, the cells are disrupted by freezing and thawing. Cell lysates are centrifuged at 1000g for 10 min at 4°C, and the supernatant is further centrifuged at 100 000g for 30 min. The resulting supernatant (S-100 fraction) is stored at −80°C. To determine caspase 3-like activity, 75 μg of protein from the S-100 fraction is incubated at 37°C with the colorimetric caspase 3 substrate N-acetyl-Asp-Glu-Val-Asp p-nitroanilide (100 mM; Ac-DEVD-pNA) and 1 mM dATP in a final volume of 120 μL. Cleavage of the caspase substrate is monitored at 405 nm using a GenTec spectrophotometer[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay
[2]

Human glioblastoma cells (U87MG, ATCC) are routinely maintained at 37°C and 5% CO2 in EMEM medium, with NEAA, containing 10% fetal bovine serum, 2 mM of glutamine, 1% penicillin and streptomycin. U87MG cells are used for no more than 15 passages. Cells are seeded in 96-well plates (5000 cells/well). After 24 h cells are treated with Epothilone B. Growth inhibition of U87MG cells is measured after 72 h of drug treatment by using the MTT cell proliferation assay[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[3]

Mice[3]
D425Med cells (6×106) are injected subcutaneously on the backs of 4-6-week-old athymic nude mice. Tumor volumes are determined from caliper measurements of tumor length (L) and width (l) according to the formula (L×l2)/2. Tumors are allowed to expand to a volume of 200 mm3 (±10%) before treatment start. With the use of a customized shielding device, mice are given strictly loco regional radiotherapy of 3×3 Gy on 3 consecutive days using a Gulmay 200 kV X-ray unit at 100 cGy/min at room temperature. Epothilone B (2 mg/kg; dissolved in 30% PEG-300/70% saline) is applied intravenously 24 h before the first treatment with ionizing radiation (at day 0 of the treatment; n=5 per group). Tumor growth is monitored daily.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 1.9697 mL 9.8487 mL 19.6974 mL 49.2436 mL
5 mM 0.3939 mL 1.9697 mL 3.9395 mL 9.8487 mL
10 mM 0.1970 mL 0.9849 mL 1.9697 mL 4.9244 mL
15 mM 0.1313 mL 0.6566 mL 1.3132 mL 3.2829 mL
20 mM 0.0985 mL 0.4924 mL 0.9849 mL 2.4622 mL
25 mM 0.0788 mL 0.3939 mL 0.7879 mL 1.9697 mL
30 mM 0.0657 mL 0.3283 mL 0.6566 mL 1.6415 mL
40 mM 0.0492 mL 0.2462 mL 0.4924 mL 1.2311 mL
50 mM 0.0394 mL 0.1970 mL 0.3939 mL 0.9849 mL
60 mM 0.0328 mL 0.1641 mL 0.3283 mL 0.8207 mL
80 mM 0.0246 mL 0.1231 mL 0.2462 mL 0.6155 mL
100 mM 0.0197 mL 0.0985 mL 0.1970 mL 0.4924 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Epothilone B
Cat. No.:
HY-17029
Quantity:
MCE Japan Authorized Agent: